QOL was assessed by patient responses to a generic cancer instrument, the QLQ-C30 and QLQ BR-23, as mentioned above.
Quality of care will be measured by the QUOTE-breast cancer instrument, cost-effectiveness of the ultra short stay programme will be measured by means of the EuroQol (administered at four time-points) and a cost book for patients.
Along with exhibits on "high-voltage X-ray treatment" of cancer, on instruments used in famous murder cases and on poisons removed from the organs of homicide victims, it said, "Here will be demonstrated the 'artificial pacemaker,' by which hearts that have stopped beating may sometimes be resuscitated".
Using this approach, we examine whether the variety of possible lung cancer measurement instruments is also reflected by research practice.
In comparison, even other lung cancer specific instruments like the FACT-L and the lung cancer symptom scale (LCSS) are only used in relatively few studies [4].
Due to a failure to identify concerns specific to cervical cancer, these instruments may not be the most suitable for assessing QOL among cervical cancer survivors.
The complex care demanded in these settings as well as the need for advanced needs assessment calls for cancer specific instruments that can perform well within these requirements as a means to improve the provided cancer care.
It is proposed that future research will assess both these differences, as well as confirm whether the difference in utility found for generic and cancer specific instruments in high income countries [ 52] is also found in for Sri Lanka.
Our findings demonstrate that since the publication of the IOM's Crossing the Quality Chasm report in 2001 [ 1], only one of 21 patient-centred cancer care instruments, the Indicators (Non-small Cell Lung Cancer) measure, included questions relating to the six IOM dimensions of patient-centred care [ 40].
The breast cancer-specific instruments mostly used along with cancer-specific instruments included European Organization for Research and Treatment of Cancer-Breast Module (EORTC QLQ-BR23) and Functional Assessment of Cancer Therapy-Breast (FACT-B).
